Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Launched by ADVERUM BIOTECHNOLOGIES, INC. · Feb 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Ixoberogene Soroparvovec (Ixo-vec) for people with a specific eye condition known as neovascular age-related macular degeneration (nAMD), which can cause vision loss. The trial is looking to see how effective a single injection of Ixo-vec is compared to another approved treatment. Researchers will measure changes in vision over the course of about a year to understand how well the new treatment works and how safe it is for patients.

To participate in this trial, individuals must be at least 50 years old and have been diagnosed with nAMD, specifically a type that involves abnormal blood vessel growth in the eye. They should also be able to provide consent and have a certain level of vision as measured by a specific test. Participants will receive regular check-ups throughout the study to monitor their vision and overall health. It’s important to note that some people, such as those with certain health conditions or recent eye surgeries, may not be eligible to join. If you or someone you know is interested, it’s a good idea to talk to a healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Able and willing to provide informed consent (or have a legally authorized representative who is able and willing to provide informed consent) prior to any study assessments and procedures and comply with the study requirements and visits.
• • 2. Male or female with a diagnosis of CNV secondary to nAMD in the study eye, with nAMD disease activity at Screening Visit 1.
• • 3. At least 50 years old at Screening Visit 1.
• • 4. An Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA letter score of 35 - 78 (approximate Snellen equivalent of 20/200 to 20/32) in the study eye at Screening Visit 1.
• • 5. Demonstrated a meaningful anatomic response to anti-VEGF therapy during screening
• • 6. Able to reliably use eye drops per protocol
• Exclusion Criteria:
• • General Exclusion Criteria
• • 1. History of a medical condition giving reasonable suspicion of a condition that contraindicates the use of Ixo-vec, compromises the participant's ability to comply with the planned study activities, or that might affect the interpretation of the results of the study or render the participant at high risk for treatment complications in the opinion of the Investigator. History of severe coronavirus disease (COVID-19) infection may meet this exclusion criteria if, in the opinion of the Investigator, it is likely to lead to any important complications.
• • 2. Received any prior gene therapy.
• • 3. Prior treatment with any non-gene therapy investigational medicinal product (IMP) or medical device in the study eye within 3 months of Screening Visit 1 or 5 half-lives of the IMP prior to dosing with Ixo-vec, whichever is longer.
• • 4. Female participants who are pregnant or breastfeeding or who intend to become pregnant or breastfeed in the future.
• 5. History or evidence of any of the following cardiovascular diseases:
• • 1. Myocardial infarction in the 6-month period prior to Day 1.
• • 2. Uncontrolled hypertension defined as systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg.
• • 3. Stroke in the 6-month period prior to Day 1.
• • 6. History of ongoing bleeding disorders
• • 7. Use of systemic immunosuppressive drugs within 90 days prior to Screening Visit 1.
• • 8. Evidence of poorly controlled diabetes or glycated hemoglobin (HbA1c) ≥ 8.0% during screening
• • Ocular Exclusion Criteria
• • 1. Any active ocular or periocular infection in the study eye from Screening Visit 1.
• 2. History or evidence of the following in the study eye:
• • 1. Intraocular or refractive surgery within 90 days prior to Screening Visit 1 (Day -56 to Day -49).
• • 2. Any previous penetrating keratoplasty or vitrectomy.
• • 3. Any previous panretinal photocoagulation.
• • 4. Any previous submacular surgery, other surgical intervention (including port delivery system) or laser treatment for age related macular degeneration.
• • 3. Any history or evidence of retinal detachment (with or without repair) or retinal pigment epithelium rip/tear in the study eye, as determined by the Investigator during screening or at Day 1.
• • 4. Uncontrolled ocular hypertension or glaucoma in the study eye from Screening Visit 1 to Week 1.
• • 5. Any history of intraocular pressure (IOP) elevation related to topical steroid administration in either eye.
• • 6. Any history of uveitis or inflammation (grade trace or above) except mild anticipated post operative inflammation that resolved in either eye.
• • 7. Any history of treatment with complement inhibitors for geographic atrophy in the study eye.
• • 8. Known history of ocular herpes simplex virus, varicella-zoster virus, or cytomegalovirus, including viral uveitis, retinitis, or keratitis in either eye.